NetworkNewsBreaks

FridayApr 28, 2017 11:33 am

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Strengthens Agent Ownership Model through Plans to Add Two Agents to Board of Directors

eXp World Holdings, Inc. (OTCQB: EXPI), holding company for the Agent-Owned Cloud Brokerage®, announced at its annual shareholder event in San Diego that two eXp Realty agents will join the company’s board of directors, furthering the company’s objective of building the most agent-centric real estate brokerage company in the industry. The new board members will be selected through an inclusive nominating process tied to the launch of the new, 12-member eXp Agent Advisory Council, with directors Jason Gesing and Gene Frederick volunteering to transition off the board over the next year to make room for these new appointments. “Agent ownership…

Continue Reading

ThursdayApr 27, 2017 2:12 pm

NetworkNewsBreaks – ProBility Media Corp. (PBYA) Aims to Occupy Leading Position in Construction Industry Training

ProBility Media (OTCQB: PBYA) recently acquired One Exam Prep LLC, gaining ground on its goal to become a leader in continuing education in the construction industry. “The company also expects its technology-driven construction training and education services to eventually be offered internationally. For now, its services are reinforcing continuous workplace learning and allowing workers all over the country to begin and advance their careers. ProBility’s unprecedented growth is showing in other ways, too. Recently, OTC Markets uplisted the company to the QB Tier, which requires annual certification and consistent reporting with the Securities and Exchange Commission. Its string of successful…

Continue Reading

ThursdayApr 27, 2017 1:00 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 27, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MTBC 66.39% – News: Signs two new health care clients KCPC 20.03% – News: Reports liver cancer immunotherapy results CDXC 17.02% – News: Enters a securities purchase agreement for the sale of up to $25M of its common stock INLX 13.33% – News: Partners with Field2Base CLRB 12.50% – News: Reports preclinical data on CLR 131 and CLR 125 DRYS 11.31% – News: Repays commercial loan facility in full RCAR 8.82% – News: Technology…

Continue Reading

ThursdayApr 27, 2017 12:57 pm

NetworkNewsBreaks – Medigus Ltd.’s (NASDAQ: MDGS) MUSE™ System for GERD Used in First 10 Patients in CFDA’s Clinical Study

Medigus (NASDAQ: MDGS) this morning said that the first 10 procedures have been performed as the initial phase of the China Food and Drug Administration (CFDA) multi-center MUSE™ clinical study. The procedures for the clinical study, which will include roughly 62 patients, have started at four hospitals in China and are expected to continue through 2017. Data from the trial is anticipated to be reported to the CFDA in 2018 as part of the company’s submission for approval to sell MUSE™ in China. “We are looking forward to a successful clinical trial in China, which will lead to higher adoption…

Continue Reading

ThursdayApr 27, 2017 12:12 pm

NetworkNewsBreaks – SinglePoint, Inc.’s (SING) Unique Strategy Aims to Remove Risk While Expanding Portfolio

SinglePoint (OTC: SING) continues to pursue strategic opportunities to widen its foothold in the cannabis industry while hedging itself against potential risks regarding the legality of marijuana. “Focused on innovation, SinglePoint is expanding its portfolio in the cannabis markets with the strategic acquisition of companies that profit from the cannabis industry but don’t touch the plant itself. There’s little doubt that the marijuana market in the United States will continue to flourish and is poised for explosive upside growth. SinglePoint’s strategy positions the company to maximize profit from the marijuana markets yet virtually eliminate any downside risk exposure. The company’s…

Continue Reading

ThursdayApr 27, 2017 12:12 pm

NetworkNewsBreaks – Conatus Pharmaceuticals, Inc. (NASDAQ: CNAT) Reiterated with ‘Buy’ Rating, $11 PT at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and a price target of $11 on Conatus Pharmaceuticals, Inc. (NASDAQ: CNAT) following the company’s recent presentation at the 2017 European Association for the Study of the Liver (EASL). The company presented two posters supporting further development of emricasan, showing that a reduction in MELD scores lowers risk of liver transplantation or death compared to patients with stable or increased MELD scores. The analyst noted that the posters signify that the continued development of emricasan is warranted. For more information, visit www.conatuspharma.com About Conatus Pharmaceuticals Conatus is a biotechnology company focused on the development…

Continue Reading

ThursdayApr 27, 2017 12:12 pm

NetworkNewsBreaks – Moxian (NASDAQ: MOXC) Generates E-Commerce Through Social Media Marketing

An April 2016 report by McKinsey & Company, Consumer China 2016 Survey (http://nnw.fm/QHb20), suggests that social media is gaining importance for companies like Moxian (NASDAQ: MOXC). “Moxian, Inc. is committed to growth in China’s online-to-offline (O2O) retail market, which is predicted by the Chinese to reach $48 billion in 1H17. Social media, an important part of Moxian’s marketing strategy, is playing a growing role in generating e-commerce apparel and dining revenues, research shows. A report by McKinsey & Company finds that the online market is changing retail buying patterns within China. Moxian is a high technology company which is transitioning…

Continue Reading

ThursdayApr 27, 2017 12:12 pm

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $41 PT on Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR)

Aegis Capital Corp. has reiterated a ‘Buy’ rating and $41 price target on the stock of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR).  The report follows the company’s recent presentation of encouraging data for eptinezumab (formerly ALD403) at the 69th Annual American Academy of Neurology (AAN) meeting. Eptinezumab is currently in phase 3 clinical development for the prevention of chronic migraines. The Aegis analyst noted that this data suggests that increases in responder rates and reductions in HIT-6 scores for eptinezumab resulted in improved quality of life for those with chronic migraines. Additional data is expected to be released in the second…

Continue Reading

ThursdayApr 27, 2017 11:49 am

NetworkNewsBreaks – ORHub, Inc. (ORHB) Successfully Collects Data from 500 Surgeries

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) today announced that, via its ORHub platform, the company has successfully collected data from 500 surgeries. “ORHub's achievement of recording more than 500 surgical cases is a clear message that our software is performing as expected and becoming a fixture in the operating room,” Wesley Mitchell, chief technology officer for ORHub, stated in the news release. “We have been the system of record for several months without issue at two major medical institutions and will be announcing additional provider participation shortly. The data we have collected is providing valuable insight that is…

Continue Reading

WednesdayApr 26, 2017 1:34 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 26, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ORRP 25.00% – News: Hosts corporate update conference call LLEX 14.00% – News: Secures new financing of $140M; receives approval to list on NYSE CETV 11.64% – News: Posts Q1 2017 financial results RTK 9.20% – News: Holding conference call to discuss Q1 2017 results on May 11 TROV 8.03% – News: Releasing Q1 2017 financial results, hosting conference call on May 10 SFIV 7.14% – News: Plans to issue forward stock split/dividend FLKS…

Continue Reading